Temozolomide-associated hypermutation in gliomas

Mechanisms of DNA damage, repair, and mutagenesis

(2017) Nimrat Chatterjee et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

(2017) Martin J van den Bent et al.   LANCET

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

(2017) D. A. Reardon et al.   NEURO-ONCOLOGY

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

(2017) Steven Lemery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid

(2016) Elena I. Pentsova et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH mutation is associated with higher risk of malignant transformation in low-grade glioma

(2016) Severina Leu et al.   JOURNAL OF NEURO-ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Clonal evolution of glioblastoma under therapy

(2016) Jiguang Wang et al.   NATURE GENETICS

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

(2016) Jan C. Buckner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

(2016) T. M. Johanns et al.   Cancer Discovery

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO

(2015) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

(2015) Hinke F. van Thuijl et al.   ACTA NEUROPATHOLOGICA

Spatiotemporal Evolution of the Primary Glioblastoma Genome

(2015) Jinkuk Kim et al.   CANCER CELL

DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors

(2015) Tali Mazor et al.   CANCER CELL

Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer

(2015) John M. Carethers et al.   GASTROENTEROLOGY

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution

(2015) Hoon Kim et al.   GENOME RESEARCH

Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424

(2015) Barbara J. Fisher et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers

(2015) Adam Shlien et al.   NATURE GENETICS

Integrated genomic characterization of IDH1-mutant glioma malignant progression

(2015) Hanwen Bai et al.   NATURE GENETICS

Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework

(2015) Michael E. Sughrue et al.   Neurosurgical Focus

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch Repair during Homologous and Homeologous Recombination

(2015) Maria Spies et al.   Cold Spring Harbor Perspectives in Biology

Hypermutation takes the driver’s seat

(2015) Matthias Schlesner et al.   Genome Medicine

Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH

(2014) J. Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC

(2014) F. Dietlein et al.   Cancer Discovery

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

(2013) Hideyuki Arita et al.   ACTA NEUROPATHOLOGICA

Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress

(2013) M Hewish et al.   BRITISH JOURNAL OF CANCER

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

(2012) Xiao-Yang Liu et al.   ACTA NEUROPATHOLOGICA

Conventional MRI evaluation of gliomas

(2012) N Upadhyay et al.   BRITISH JOURNAL OF RADIOLOGY

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

(2011) Jörg Felsberg et al.   INTERNATIONAL JOURNAL OF CANCER

Low-grade gliomas in adults

(2011) Nader Sanai et al.   JOURNAL OF NEUROSURGERY

DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1

(2010) Sarah A. Martin et al.   CANCER CELL

DNA mismatch repair and the DNA damage response to ionizing radiation: Making sense of apparently conflicting data

(2010) Lynn M. Martin et al.   CANCER TREATMENT REVIEWS

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis

(2010) K. A. Jaeckle et al.   JOURNAL OF NEURO-ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

(2009) S. Yip et al.   CLINICAL CANCER RESEARCH

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair geneMSH2

(2009) Sarah A. Martin et al.   EMBO Molecular Medicine

Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide

(2009) Martin Glas et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation

(2008) Jeremy Rees et al.   EUROPEAN JOURNAL OF RADIOLOGY

Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

(2008) Justin S. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE